Factors associated with FEV₁decline in cystic fibrosis: analysis of the ECFS Patient Registry

Abstract

Pulmonary insufficiency is the main cause of death in cystic fibrosis (CF). We analysed forced expiratory volume in 1 s (FEV1) data of 14 732 patients registered in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database in 2007. We used linear and logistic regressions to investigate associations between FEV1 % predicted and clinical outcomes.Body mass index (BMI), chronic infection by Pseudomonas aeruginosa, pancreatic status and CF-related diabetes (CFRD) showed a statistically significant (all p,0.0001) and clinically relevant effect on FEV1 % pred after adjusting for age. Patients with a lower BMI experience a six-fold increased odds ratio (95% CI 5.0-7.3) of having severe lung disease (FEV1 ,40% pred) compared to patients with normal BMI. Being chronically infected with P. aeruginosa increases the odds ratio of severe lung disease by 2.4 (95% CI 2.0-2.7), and patients with pancreatic insufficiency experience a 2.0-fold increased odds ratio (95% CI 1.6-2.5) of severe lung disease compared to pancreatic sufficient patients. Patients with CFRD have a 1.8-fold increased odds ratio (95% CI 1.6-2.2) compared to patients not affected.These potential risk factors for pulmonary disease in patients with CF are to some degree preventable or treatable. We emphasise the importance of their early identification through frequent routine tests, the implementation of infection control measures, and a timely initiation of relevant therapies. @ERSpublications Independent effect of nutrition, chronic Pseudomonas aeruginosa infection and CF-related diabetes on FEV1 in CF patients

Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review

“…Despite these improvements, pulmonary insufficiency remains as the main cause of death in CF and there are strong associations between growth and nutritional indices and lung function 19. However, most studies reporting these evidences are cross-sectional, with few evidences to support association between longitudinal changes in growth and nutrition with changes in lung function through life.…”

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

“…Cystic fibrosis (CF) lung disease is characterized by chronic respiratory tract infection with multiple bacterial species frequently dominated by Pseudomonas aeruginosa 1 , which has been associated with accelerated lung disease progression, increased morbidity, and decreased survival [2][3][4] . Chronic P. aeruginosa infection is typically treated with chronic inhaled antibiotics to suppress infection, reduce risk of pulmonary exacerbations, improve quality of life, and preserve lung function 5,6 .…”

Cystic Fibrosis and the Nervous System

“…CFRD is associated with more frequent pulmonary exacerbations, 112 more severe lung disease, 113 and greater mortality. 114 Prior to the development of overt diabetes, people with CF display a spectrum of glucose tolerance abnormalities.…”